Showing 3281-3290 of 5773 results for "".
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev
- Study Shows Efficient AAV Delivery of Large Genes Using ViGeneron's REVeRT Technologyhttps://modernod.com/news/study-shows-efficient-aav-delivery-of-large-genes-using-vigenerons-revert-technology-1/2481913/ViGeneron announced a peer-reviewed publication in
- Samsung Bioepis' Byooviz Approved as Interchangeable with Lucentishttps://modernod.com/news/samsung-bioepis-byooviz-approved-as-interchangeable-with-lucentis/2481912/Samsung Bioepis annoounced that the FDA has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product interchangeable with Lucentis (ranibizumab). The FDA originally approved Byooviz in September 2021 a
- Endogena Therapeutics Secures FDA Green Light to Initiate Trials for Geographic Atrophy Treatmenthttps://modernod.com/news/endogena-therapeutics-secures-fda-green-light-for-breakthrough-amd-treatment/2481909/Endogena Therapeutics announced that the FDA has granted clearance for Endogena's investigational new drug (IND) application, allowing the company to commence a first-in-human study in 2024 for its geographic atrophy drug cadidate EA 2351. This milestone marks the com
- Harrow Completes Transfer of NDAs and Launches Branded Ophthalmic Portfolio in the UShttps://modernod.com/news/harrow-completes-transfer-of-ndas-and-launches-branded-ophthalmic-portfolio-in-the-us/2481906/Harrow announced the completion of the transfer to Harrow of the new drug applications for the following products: Flarex (fluorometholone acetate ophthalmic suspension) 0.1%, a corticosteroid indicated for use in the treatment of steroid-responsive inflamm
- The Lancet Publishes 24-Month Results from Phase 3 Studies of Syfovre for GAhttps://modernod.com/news/the-lancet-publishes-24-month-results-from-phase-3-studies-of-syfovre-for-geographic-atrophy/2481901/Apellis Pharmaceuticals announced that The Lancet has published 24-month results from the phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection)
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- FDA Approves Orasis Pharmaceuticals' Presbyopia Eye Drop Qlosihttps://modernod.com/news/fda-approves-orasis-pharmaceuticals-presbyopia-eye-drop-qlosi/2481896/Orasis Pharmaceuticals announced that the FDA has approved Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. Qlosi is expected to be commercially available in the US in the first half of 2024. Qlosi is a p
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of
- Optos Unveils New Retinal Imaging Technology at Euretinahttps://modernod.com/news/optos-unveils-new-retinal-imaging-technology-at-euretina/2481893/Optos announced advances to its ultra-widefield multimodal retinal imaging at its satellite symposia at the Euretina congress in Amsterdam. Optos’ devices capture ultra-widefield (UWFTM) high-resolution optomap images of 200 degress of the retina in a sing